Shire PLC (LSE:SHP) - Share price


Stock Report

Shire PLC SHP

Last Price
£-

Day Change
-|-%

As of -
- | GBP
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap43.06Bil
52-Wk Range-
Yield %-
ISINJE00B2QKY057
Volume-
P/E-
P/S-
P/CF-

Share Price

Total Returns 08/01/2019

 Chg (%)  
More ...
Shire PLC3.42 
FTSE 100 TR GBP1.84
 
Financials
201520162017
More ...
Income Statement
Turnover6,416.7011,396.6015,160.60
Operating Profit1,542.501,951.703,397.20
Net Profit1,337.50603.504,253.50
Reported EPS2.260.774.66
Balance Sheet
Current Assets2,255.507,539.507,608.40
Non Current Assets14,354.3059,495.9060,148.50
Total Assets16,609.8067,035.4067,756.90
Current Liabilities3,706.107,743.307,882.00
Total Liabilities---
Total Equity9,829.1028,948.0036,176.40
Cash Flow
Operating Cash Flow2,337.002,658.904,256.70
Net Change in Cash-2,843.90392.50-63.50

Regulatory News

DateAuthor Headline
22/03/2019David Brenchley UK Equities: Where to Invest Amid Brexit Uncertainty
While many investors continue to shun UK stocks until the Brexit fog clears, others think they're too cheap to ignore. A trio of fund managers tell us where they are investing
14/07/2014Emma Wall Woodford's Full Portfolio Revealed
Woodford is maximising his overseas exposure and allocating a third of the portfolio to his favourite sector, pharmaceuticals, as well as a surprisingly high financials exposure
24/10/2012Alanna Petroff Fund Managers’ Favourites: Contrarian Edge
James Henderson, manager of two Silver-rated trusts at Henderson Global Investors, explains his contrarian investment strategy within the UK market
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
03/01/2019Exercise of OptionDr. Flemming Ornskov31.68136,8034,333,919.00
03/01/2019Exercise of OptionDr. Flemming Ornskov30.5356,9521,738,745.00
03/01/2019Exercise of OptionDr. Flemming Ornskov56.18102,5225,759,686.00
03/01/2019Exercise of OptionDr. Flemming Ornskov53.81129,9876,994,159.00

Company Profile

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Sector

Biotechnology

Index

FTSE 350 , FTSE Eurotop 300

Next Event 14/02/2019

Final Results
Ratios
Comp
More ...
PER (E)11.02
Div Yld (E)0.56
PEG (E)0.00
ROCE4.13
Op Mrgn0.22
EPS Grwth1.94
Dividends
PreviousLatest
More ...
Record Date09/03/1807/09/18
Ex-Div08/03/1806/09/18
Paid24/04/1819/10/18
Amnt21.464.26
Directors
More ...
Executive Director, Chief Financial OfficerMr Thomas Johannes Willi Dittrich
Non-Executive DirectorMr. Albert P L Stroucken
Executive Director, Chief Executive OfficerDr. Flemming Ornskov
Non-Executive DirectorMr. Dominic Blakemore
Non-Executive DirectorMr. William Burns
Non-Executive DirectorMs. Gail D Fosler
Non-Executive DirectorDr. David Ginsburg
Non-Executive DirectorMs. Anne Minto OBE
Non-Executive Director, ChairmanMs. Susan S Kilsby
Non-Executive DirectorMs. Sara Mathew
Non-Executive DirectorDr. Steven Gillis
Non-Executive DirectorMr. Ian T. Clark
Non-Executive DirectorOlivier Bohuon
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.